Agranulocytosis induced by multidrug therapy in leprosy treatment: a case report.
Multidrug therapy (WHO/MDT) in multibacillary leprosy consists of treatment with rifampicin, dapsone and clofazimine. However, adverse effects can cause the patient to abandon treatment. We report on a patient who presented agranulocytosis and hemolytic anemia associated with this treatment regime. We also examined the importance of laboratory exams for diagnosis and follow-up of the patient, and for early detection of adverse effects,with a view to improving adhesion to treatment and contributing to the eradication of Hansen's disease as a public health issue.
Silva
Itathiana Ma C B da
IM
Infectious Diseases Service, Federal University of Paraíba, João pessoa, PB, Brazil. itathiana.silva@yahoo.com.br
Oliveira
Caroline A P de
CA
Guedes
Wilma R C de A
WR
Oliveira
Benedito Bruno de
BB
Oliveira
Doris Amorim Pontes de
DA
Guedes Filho
Gilson
G
D000328:Adult; D000380:Agranulocytosis / Q000139:chemically induced*; D000743:Anemia, Hemolytic / Q000139:chemically induced*; D002991:Clofazimine / Q000009:adverse effects; D003622:Dapsone / Q000009:adverse effects; D004359:Drug Therapy, Combination / Q000009:adverse effects; D005260:Female; D006801:Humans; D007917:Leprostatic Agents / Q000009:adverse effects*; D007918:Leprosy / Q000188:drug therapy; D012293:Rifampin / Q000009:adverse effects
D007917:Leprostatic Agents; D003622:Dapsone; D002991:Clofazimine; D012293:Rifampin